InDevR is a biotechnology company poised to significantly impact vaccine process optimization and manufacturing with powerful new protein characterization tools. With a strong history of non-dilutive funding raises, including a $14.7M BARDA contract to develop a high information content influenza diagnostic and recent investment from the Bill & Melinda Gates Foundation to advance measles and rubella vaccine characterization, InDevR has launched several successful life science tool-based product lines including VaxArray and Cypher One.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/12/19 | $7,000,000 | Series A |
Adjuvant Capital | undisclosed |
